Trying to dig up some DD on $NBY this is what ive found:
9/3/14
NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, and China Pioneer Pharma Holdings, Limited (HK Stock Code: 01345), a leading marketer of branded pharmaceutical products and medical devices in China, today announced that China’s Food and Drug Administration has cleared NovaBay’s NeutroPhase® Skin and Wound Cleanser for sale throughout mainland China. NovaBay will be shipping NeutroPhase to China in the fourth quarter of 2014 to support Pioneer’s launch of the product in early 2015.
12/2/13
Item 1.01 Entry into a Material Definitive Agreement.
On November 25, 2013, NovaBay Pharmaceuticals, Inc. entered into a Common Stock Purchase Agreement (the "Agreement") with Pioneer Pharma (Singapore) Pte. Ltd. ("Pioneer"), pursuant to which: (a) Pioneer agreed to purchase from NovaBay, and NovaBay agreed to sell to Pioneer, five million shares of NovaBay's common stock for aggregate gross proceeds to NovaBay of $5.7 million; and (b) NovaBay and Pioneer agreed to cancel two warrants held by Pioneer to purchase an aggregate of two million shares of NovaBay's common stock for aggregate gross proceeds of $3.0 million, and the obligation of Pioneer to exercise the warrants pursuant to a Warrant Amendment Agreement entered into between NovaBay and Pioneer on May 9, 2013. The purchase of the five million shares is subject to customary closing conditions, including the receipt of regulatory clearance of the sale.
? Wound Care - NeutroPhase? our FDA 510(k)-cleared product for advanced wound care. With a distinct mechanism of action from Aganocides, we believe that NeutroPhase is the only patented pure hypochlorous acid solution available having the potential to be best suited to treat the six-million-patients in the U.S. who suffer from chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers.
NovaBay has begun securing commercial partnerships for NeutroPhase. In January 2012, NovaBay announced it had entered into a strategic marketing agreement with Pioneer Pharma Co., Ltd., a Shanghai-based company that markets high-end pharmaceutical products into China, to market NeutroPhase in China. In September 2012, the collaboration with Pioneer Pharma was expanded to include other Asian markets such as Hong Kong, Macau, Taiwan, Singapore, Malaysia, Indonesia, Myanmar, Philippines, Thailand, Vietnam, Brunei, Cambodia and Laos. NovaBay signed a distribution with Shin Poong Pharmaceuticals covering the Korean market during 2013 and expects to announce additional marketing agreements in select geographic markets around the world during 2013 and beyond.
NovaBay has begun securing commercial partnerships for NeutroPhase. In January 2012, NovaBay announced it had entered into a strategic marketing agreement with Pioneer Pharma Co., Ltd., a Shanghai-based company that markets high-end pharmaceutical products into China, to market NeutroPhase in China. In September 2012, the collaboration with Pioneer Pharma was expanded to include other Asian markets such as Hong Kong, Macau, Taiwan, Singapore, Malaysia, Indonesia, Myanmar, Philippines, Thailand, Vietnam, Brunei, Cambodia and Laos. NovaBay signed a distribution with Shin Poong Pharmaceuticals covering the Korean market during 2013 and expects to announce additional marketing agreements in select geographic markets around the world during 2013 and beyond.
